Dr Paul Vasey was born in Newcastle, UK and qualified MBChB in Scotland in 1988. He completed general internal medicine training in 1991 and was the Cancer Research UK Clinical Research fellow and Clinical Lecturer in the Department of Oncology, University of Glasgow, Scotland from 1992-1996. During this time of clinical and laboratory research he obtained MSc in clinical pharmacology (1994) in addition to MD (1996) with the thesis entitled ‘Invitro Studies of Cisplatin-resistant Human Ovarian Carcinoma Cells’.

From 1996-2003 Dr Vasey was the Cancer Research UK Senior Lecturer in medical oncology and honorary consultant in medical oncology at the prestigious Beatson Oncology Centre in Glasgow, Scotland. In 2003 he was promoted to Reader at the University of Glasgow. From 2001-2004 he was the Director of the West of Scotland Clinical Trials Unit (CTU) and in 2002, under Dr Vasey’s leadership, this unit was awarded Cancer Research UK’s highest award, Alpha*.

In June 2004 Dr Vasey moved to Australia and became a fellow of the Royal Australasian College of Physicians (FRACP) in March 2005. He held appointments with the University of Queensland as Associate Professor, and as an Honorary Associate of the University of Sydney.

Dr Vasey has research interests in women’s cancers and genitourinary cancers, having been the chairman of the Scottish Gynaecologic Cancer Trials Group and an executive board member on a number of UK national genitourinary and gynaecologic cancer trials national steering groups. He was the inaugural author of the ESMO Guidelines for the Treatment of Ovarian Cancer. Dr Vasey has over 200 publications including textbooks, peer-reviewed journals, conference contributions and other outputs.

Dr Vasey entered private practice with the ICON group in 2006. He is a visiting senior medical oncologist at the Wesley Hospital in Brisbane, and consults weekly at St Andrew’s Private Hospital in Ipswich

Dr Vasey combines a strong research background with a compassionate and supportive approach to patient care. He has devoted his career to advancing treatment for malignant disease and obtaining the most cutting edge, evidence-based therapies for his patients.